Orchard Therapeutics plc Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2018 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Orchard Therapeutics plc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2018 to Q3 2023.
  • Orchard Therapeutics plc Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2023 was -$35.3M, a 25.7% increase year-over-year.
  • Orchard Therapeutics plc Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2023 was -$72.9M, a 59.3% increase year-over-year.
  • Orchard Therapeutics plc annual Net Income (Loss) Attributable to Parent for 2022 was -$151M, a 4.2% decline from 2021.
  • Orchard Therapeutics plc annual Net Income (Loss) Attributable to Parent for 2021 was -$145M, a 4.87% increase from 2020.
  • Orchard Therapeutics plc annual Net Income (Loss) Attributable to Parent for 2020 was -$152M, a 7% increase from 2019.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 -$72.9M -$35.3M +$12.2M +25.7% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 -$85.2M -$12.3M +$38.6M +75.8% Apr 1, 2023 Jun 30, 2023 10-Q 2023-11-13
Q1 2023 -$124M -$17.4M +$26.9M +60.7% Jan 1, 2023 Mar 31, 2023 10-Q 2023-11-13
Q4 2022 -$151M -$7.88M +$28.5M +78.3% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-14
Q3 2022 -$179M -$47.6M -$11.1M -30.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$168M -$50.9M -$14.3M -39.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-13
Q1 2022 -$154M -$44.3M -$9.11M -25.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-13
Q4 2021 -$145M -$36.3M -$2.73M -8.11% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-14
Q3 2021 -$142M -$36.4M -$16.2M -79.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$126M -$36.6M +$10.9M +22.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-14
Q1 2021 -$137M -$35.2M +$15.4M +30.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-14
Q4 2020 -$152M -$33.6M +$11.8M +26% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-02
Q3 2020 -$164M -$20.3M +$16.4M +44.8% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$180M -$47.5M +$3.03M +6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-04
Q1 2020 -$183M -$50.6M -$19.8M -64.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-04
Q4 2019 -$163M -$45.4M -$20.4M -81.2% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-02
Q3 2019 -$143M -$36.7M -$2.85M -8.41% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-02
Q2 2019 -$140M -$50.5M +$106M +67.7% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-02
Q1 2019 -$246M -$30.7M -$15.4M -101% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-02
Q4 2018 -$230M -$25.1M Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 -$33.9M Jul 1, 2018 Sep 30, 2018 10-K 2020-02-27
Q2 2018 -$156M Apr 1, 2018 Jun 30, 2018 10-K 2020-02-27
Q1 2018 -$15.3M Jan 1, 2018 Mar 31, 2018 10-K 2020-02-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.